NeuroPace Analyst Price Targets

Wall Street analyst price targets and consensus rating for NeuroPace (NPCE).

Price Target Range — 12 Quarters

Analyst Consensus — 9 Analysts

9Buy

Consensus RatingOverweight# Analysts9Avg. Consensus PT$18Upside to Avg. PT+39.6%

Rating Trend — Last 9 Months

Recent Analyst Actions

See all ratings →

Date	Firm	Analyst	Action	Rating Change	Price Target
Sep 18, 2026	Keybanc	Brett Fishbin	Initiate	Overweight	$18
Jul 29, 2026	HC Wainwright & Co.	Yi Chen	Maintained	Buy	$20
Jul 23, 2026	Mizuho	Anthony Petrone	Initiate	Outperform	$22
May 15, 2026	HC Wainwright & Co.	Yi Chen	PT Raise	Buy	$19→$20
Jan 27, 2026	HC Wainwright & Co.	Yi Chen	PT Raise	Buy	$18→$19
Dec 16, 2025	UBS	Priya Sachdeva	PT Raise	Buy	$18→$22
Dec 10, 2025	JP Morgan	Rohin Patel	PT Raise	Overweight	$18→$20
Nov 5, 2025	JP Morgan	Rohin Patel	PT Raise	Overweight	$16→$18
Nov 5, 2025	Wells Fargo	Vik Chopra	PT Raise	Overweight	$15→$16
Aug 13, 2025	Wells Fargo	Vik Chopra	PT Cut	Overweight	$17→$15
May 28, 2025	HC Wainwright & Co.	Yi Chen	Initiate	Buy	$18
May 14, 2025	JP Morgan	Robbie Marcus	PT Raise	Overweight	$14→$16
May 14, 2025	Cantor Fitzgerald	Ross Osborn	Maintained	Overweight	$17
Apr 14, 2025	Cantor Fitzgerald	Ross Osborn	PT Cut	Overweight	$20→$17
Mar 5, 2025	Cantor Fitzgerald	Ross Osborn	PT Raise	Overweight	$19→$20
Jan 30, 2025	Wells Fargo	Larry Biegelsen	PT Raise	Overweight	$13→$17
Jan 21, 2025	UBS	Priya Sachdeva	Initiate	Buy	$17
Dec 17, 2024	JP Morgan	Robbie Marcus	PT Raise	Overweight	$9→$14
Nov 13, 2024	Wells Fargo	Vik Chopra	PT Cut	Overweight	$15→$13
Aug 14, 2024	Cantor Fitzgerald	Ross Osborn	Maintained	Overweight	$18

More with Benzinga EdgeGet Access

Analyst Ratings News

This Cue Biopharma Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Friday

Analysts initiated bullish coverage on TRAX, BGSI, NPCE, CUE and NGVC, assigning Outperform/Buy ratings with price targets from $18 to $120.

Avi Kapoor

PRO
Keybanc Initiates Coverage On NeuroPace with Overweight Rating, Announces Price Target of $18

Keybanc analyst Brett Fishbin initiates coverage on NeuroPace (NASDAQ:NPCE) with a Overweight rating and announces Price Target of $18.

Benzinga Newsdesk

PRO
HC Wainwright & Co. Reiterates Buy on NeuroPace, Maintains $20 Price Target

HC Wainwright & Co. analyst Yi Chen reiterates NeuroPace (NASDAQ:NPCE) with a Buy and maintains $20 price target.

Benzinga Newsdesk

PRO
Mizuho Initiates Coverage On NeuroPace with Outperform Rating, Announces Price Target of $22

Mizuho analyst Anthony Petrone initiates coverage on NeuroPace (NASDAQ:NPCE) with a Outperform rating and announces Price Target of $22.

Benzinga Newsdesk

PRO
HC Wainwright & Co. Maintains Buy on NeuroPace, Raises Price Target to $20

HC Wainwright & Co. analyst Yi Chen maintains NeuroPace (NASDAQ:NPCE) with a Buy and raises the price target from $19 to $20.

Benzinga Newsdesk

Beyond The Numbers: 5 Analysts Discuss NeuroPace Stock

Benzinga Insights

NeuroPace Inc

NeuroPace Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

This Cue Biopharma Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Friday

PRO
Keybanc Initiates Coverage On NeuroPace with Overweight Rating, Announces Price Target of $18

PRO
HC Wainwright & Co. Reiterates Buy on NeuroPace, Maintains $20 Price Target

PRO
Mizuho Initiates Coverage On NeuroPace with Outperform Rating, Announces Price Target of $22

PRO
HC Wainwright & Co. Maintains Buy on NeuroPace, Raises Price Target to $20

Beyond The Numbers: 5 Analysts Discuss NeuroPace Stock

People Also Watch

People Also Watch

NeuroPace Inc

NeuroPace Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

This Cue Biopharma Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Friday

PROKeybanc Initiates Coverage On NeuroPace with Overweight Rating, Announces Price Target of $18

PROHC Wainwright & Co. Reiterates Buy on NeuroPace, Maintains $20 Price Target

PROMizuho Initiates Coverage On NeuroPace with Outperform Rating, Announces Price Target of $22

PROHC Wainwright & Co. Maintains Buy on NeuroPace, Raises Price Target to $20

Beyond The Numbers: 5 Analysts Discuss NeuroPace Stock

People Also Watch

People Also Watch

PRO
Keybanc Initiates Coverage On NeuroPace with Overweight Rating, Announces Price Target of $18

PRO
HC Wainwright & Co. Reiterates Buy on NeuroPace, Maintains $20 Price Target

PRO
Mizuho Initiates Coverage On NeuroPace with Outperform Rating, Announces Price Target of $22

PRO
HC Wainwright & Co. Maintains Buy on NeuroPace, Raises Price Target to $20